These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 36185807)

  • 1. Immunotherapy approaches for the treatment of diffuse midline gliomas.
    Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
    Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas.
    Das AK; Sinha M; Singh SK; Chaudhary A; Boro AK; Agrawal M; Bhardwaj S; Kishore S; Kumari K
    Acta Neurol Belg; 2024 Aug; 124(4):1251-1261. PubMed ID: 38669002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
    Majzner RG; Ramakrishna S; Yeom KW; Patel S; Chinnasamy H; Schultz LM; Richards RM; Jiang L; Barsan V; Mancusi R; Geraghty AC; Good Z; Mochizuki AY; Gillespie SM; Toland AMS; Mahdi J; Reschke A; Nie EH; Chau IJ; Rotiroti MC; Mount CW; Baggott C; Mavroukakis S; Egeler E; Moon J; Erickson C; Green S; Kunicki M; Fujimoto M; Ehlinger Z; Reynolds W; Kurra S; Warren KE; Prabhu S; Vogel H; Rasmussen L; Cornell TT; Partap S; Fisher PG; Campen CJ; Filbin MG; Grant G; Sahaf B; Davis KL; Feldman SA; Mackall CL; Monje M
    Nature; 2022 Mar; 603(7903):934-941. PubMed ID: 35130560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
    Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
    Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
    de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M
    Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
    Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
    Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of socioeconomic status on clinical outcomes of diffuse midline glioma and diffuse intrinsic pontine glioma.
    Lee JH; Holste KG; Bah MG; Franson AT; Garton HJL; Maher CO; Muraszko KM
    J Neurosurg Pediatr; 2024 Jun; 33(6):507-515. PubMed ID: 38489807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.
    Wang SS; Davenport AJ; Iliopoulos M; Hughes-Parry HE; Watson KA; Arcucci V; Mulazzani M; Eisenstat DD; Hansford JR; Cross RS; Jenkins MR
    Neurooncol Adv; 2023; 5(1):vdad024. PubMed ID: 37152812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.
    Ausejo-Mauleon I; Labiano S; de la Nava D; Laspidea V; Zalacain M; Marrodán L; García-Moure M; González-Huarriz M; Hervás-Corpión I; Dhandapani L; Vicent S; Collantes M; Peñuelas I; Becher OJ; Filbin MG; Jiang L; Labelle J; de Biagi-Junior CAO; Nazarian J; Laternser S; Phoenix TN; van der Lugt J; Kranendonk M; Hoogendijk R; Mueller S; De Andrea C; Anderson AC; Guruceaga E; Koschmann C; Yadav VN; Gállego Pérez-Larraya J; Patiño-García A; Pastor F; Alonso MM
    Cancer Cell; 2023 Nov; 41(11):1911-1926.e8. PubMed ID: 37802053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic virotherapy for the treatment of pediatric brainstem gliomas.
    Gállego Pérez-Larraya J; García-Moure M; Alonso MM
    Rev Neurol (Paris); 2023 Jun; 179(5):475-480. PubMed ID: 37061388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
    Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
    Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
    Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
    Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.
    Miguel Llordes G; Medina Pérez VM; Curto Simón B; Castells-Yus I; Vázquez Sufuentes S; Schuhmacher AJ
    J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629304
    [No Abstract]   [Full Text] [Related]  

  • 15. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
    Gwak HS; Park HJ
    Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
    Vitanza NA; Monje M
    Curr Treat Options Neurol; 2019 Jul; 21(8):37. PubMed ID: 31290035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma.
    Arms LM; Duchatel RJ; Jackson ER; Sobrinho PG; Dun MD; Hua S
    J Control Release; 2024 Jun; 370():835-865. PubMed ID: 38744345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.